Estrogen hormone therapy in older women may reduce signs of Alzheimer’s

A comprehensive survey, involving more than 21,000 participants, revealed that women undergoing estrogen-only hormone replacement therapy at older ages had a lower incidence of dementia and fewer indicators of Alzheimer’s disease in the brain. The survey indicated a 39% decrease in the probability of being diagnosed with dementia and a 35% reduction in the occurrence of brain markers associated with Alzheimer’s in post-mortem exams, such as amyloid plaques and tau protein tangles. Additionally, biomarker analyzes pointed to less amyloid accumulation among women who received the therapy.
Study points to possible link between estrogen and lower incidence of dementia
Extensive research has suggested that estrogen-only hormone replacement therapy, performed later in women’s lives, is linked to a marked decrease in the risk of dementia and less brain evidence of Alzheimer’s disease.
Extensive research has identified that participants who opted for hormone therapy later in life were less likely to develop dementia. The findings were released on August 12, 2026 in Neurology, a scientific publication of the American Academy of Neurology.
The experts involved in the study were keen to point out that the data reveal a connection between the factors, but do not establish definitive proof that hormone therapy is capable of preventing the onset of dementia.
“While these findings contribute to an improved understanding of the relationship between hormone therapy and various indicators of dementia, it is essential that further investigations be carried out before accurate guidance can be provided to women about using these approaches for brain health,” said Jennifer Bruno, PhD in philosophy at Stanford Medicine in Stanford, California, lead author of the work. She added that “this research examined women who had been using hormone therapy for decades, with different modalities and times of application than contemporary practices; therefore, although the results are valuable, they may not be applicable to current protocols.”
Analysis included more than 21 thousand female participants
The academics reviewed clinical data from two broad databases, totaling 21,462 women who underwent medical evaluations while alive. Of this total, 728 individuals underwent brain imaging or biomarker tests. Another 2,959 participants had their brains examined post-mortem, with an average age of 82 years, making it possible to search for signs of Alzheimer’s disease.
The volunteers in both data groups were monitored for an approximate period of three to five years, with the beginning of monitoring occurring at an average age of 71 years.
Of the universe studied, 1,953 women used hormone therapy, while 19,509 did not use it. The average age for starting therapy among participants who received it was over 70 years old.
Research has focused exclusively on estrogen-only therapy. Previous research has indicated that treatment combining estrogen and progestin may be linked to an increased risk of dementia. In the context of current medicine, estrogen-alone therapy is generally recommended only for individuals who have undergone a hysterectomy to mitigate the risk of endometrial cancer.

Reduction of Alzheimer’s markers in post-mortem examinations
Among women who had their brains analyzed post-mortem, those who underwent hormone therapy were less likely to exhibit signs of Alzheimer’s disease.
Scientists investigated three primary indicators linked to Alzheimer’s: beta-amyloid plaques, tau protein neurofibrillary tangles, and neuritic plaques — the latter being clusters of amyloid surrounded by compromised nerve cells. Such findings were integrated into a single score developed to quantify the extent of Alzheimer’s pathology in brain tissue.
In the group of women who underwent hormone therapy, 18% did not show any signs of Alzheimer’s disease in their autopsies. On the other hand, only 10% of those who did not receive treatment were free of these signs.
On the other hand, 40% of women who used hormone therapy exhibited the three markers of Alzheimer’s disease, compared to 51% of those who did not adhere to treatment.
Even after adjusting for variables such as age, educational level, genetic factors, ethnicity and hypertension, the use of hormone therapy remained linked to a 35% reduction in the probability of detecting signs of Alzheimer’s disease in post-mortem examinations.
Biomarkers indicate reduction in amyloid accumulation
A separate investigation analyzed biomarker tests collected from participants while they were still alive. Women who received hormone therapy revealed concentrations of amyloid biomarkers in their blood and cerebrospinal fluid that are consistent with lower brain amyloid deposition compared to those who did not receive treatment.
Elevated concentrations of beta-amyloid protein in the blood and cerebrospinal fluid may be an indication that a smaller amount of this protein is accumulating in the brain in the form of plaques.
Adherence to hormone therapy was also correlated with a 39% decrease in the chance of obtaining a clinical diagnosis of dementia. Additionally, women undergoing treatment showed a lower incidence of memory difficulties or reduced ability to perform daily tasks.
Differences between study results and current hormonal practice
A relevant caveat highlighted is that the profile of hormone therapy use by women in this study differs from current prescription protocols. Jennifer Bruno noted that participants who underwent hormone therapy were, on average, 70 years old.
Contemporary medical management typically recommends starting hormone therapy between the late 40s and early 50s, with stopping treatment recommended before the age of 60.
“Despite inherent limitations, our findings provide clear indications of a connection between the application of estrogen-alone hormone therapy later in life and more favorable outcomes with regard to dementia and brain integrity,” said Jennifer Bruno.
The research project received financial support from the National Institute on Aging.






